Aragon is a pharmaceutical company with a focus on creating treatments for hormonally-driven cancers (such as prostate, breast or ovarian). The company has one product in a Phase I/II clinical trial and is working on others designed to both block and destroy hormone receptors that drive tumor growth.
(VC funding raised in 2012: $87.8 million)